If any of the following side effects occur while taking alefacept, check with your doctor or nurse immediately:
Immunologic side effects including dose-dependent reductions in circulating CD+ and CD+ T lymphocyte counts have been reported.
The total percentage of alefacept-treated patients hospitalized for cardiovascular events was .
Cardiovascular side effects including coronary artery disorder (<) and myocardial infarction (<) have been the adverse reactions which most commonly resulted in clinical intervention.
Twenty five of the , patients who received alefacept (the active ingredient contained in Amevive) were diagnosed with a total of  treatment-emergent malignancies.
Six cases were basal cell and seventeen cases were squamous cell cancers of the skin.
Three cases of lymphoma have been reported; one was classified as non-Hodgkin's follicle-center cell lymphoma and two were classified as Hodgkin's disease.
Oncologic side effects including malignancies have been reported.
Postmarketing reports of malignancies including skin, solid organ, lymphomas and leukemias have also been received.
Chills have been reported to occur predominantly with intravenous administration.
General side effects including chills , dizziness, headache, and accidental injury have been reported.
Postmarketing reports of sepsis and opportunistic infections (viral, fungal, and bacterial) have been received.
Local side effects including injection site pain and injection site inflammation have been reported.
Gastrointestinal side effects including nausea have been reported.
Postmarketing reports of clostridium difficile colitis have been received.
Respiratory side effects including pharyngitis and increased cough have been reported.
Postmarketing reports of pharyngitis have also been received.
Dermatologic side effects including pruritus have been reported.
Postmarketing reports of cellulitis have been received.
Musculoskeletal side effects including myalgia have been reported.
Hepatic side effects including postmarketing reports of asymptomatic transaminase elevation, fatty infiltration of the liver, hepatitis, and severe liver failure have been received.
Genitourinary side effects including postmarketing reports of urinary tract infection have been received.
Chills
cough
fever
hoarseness
lower back or side pain
painful or difficult urination
Body aches or pain
congestion
dryness or soreness of the throat
runny nose
tender, swollen glands in the neck
trouble with swallowing
voice changes
Arm, back, or jaw pain
chest pain or discomfort
chest tightness or heaviness
fast or irregular heartbeat
nausea
pain or discomfort in the arms, jaw, back, or neck
shortness of breath
sweating
vomiting
Pain, swelling, bleeding, skin rash, or lumps at the injection site
Difficulty with moving
dizziness
itching skin
joint pain
muscle aching or cramping
muscle pains or stiffness
swollen joints
Headache